Epigenetic regulation allows heritably modulating gene expression profiles without modifying the primary sequence of gDNA. Under physiologic conditions, epigenic patterns determine tissue-specific gene expression landscapes, gene imprinting, inactivation of chromosome X, and preservation of genomic stability. The most characterized mediators of epigenetic inheritance are gDNA methylation and histone posttranslational modifications that cooperate to alter chromatin state and genome transcription. According to these notions, it is not surprising that cancer cells invariably deploy epigenetic alterations to achieve gene expression patterns required for neoplastic transformation and tumor progression. In this context, the recently uncovered use of epigenetic alterations by cancer cells to become stealth from the host’s immune recognition has significant immunobiologic relevance in tumor progression, and it appears to have potential clinical usefulness. Indeed, immune evasion is among the major obstacles to further improve the efficacy of cancer immunotherapies and to increase long-lasting disease control. Luckily, different "epigenetic drugs" able to revert these "epimutations" are available, some of which have already been approved for clinical use. Here, we summarize the immunomodulatory activities of epigenetic drugs that lead to improved immune recognition of cancer cells and focus on the potential of this class of agents in improving the anticancer activity of novel immunotherapies through combinatorial epigenetic immunotherapy approaches.

Background

The clinical potential of cancer immunotherapy relies on the well-established notion that the immune system can efficiently eradicate cancer cells being recognized as non-self. This anticancer activity results from a series of genetic, epigenetic, and regulatory modifications occurring along with neoplastic transformation that lead to an altered cell membrane molecular repertoire, as well as to a de novo or upregulated expression of tumor-associated antigens (TAA). Immune recognition of neoplastic cells is mainly accomplished by innate and adaptive immune responses. The former is not antigen specific and relies mainly on the activity of natural killer (NK) cells to recognize transformed cells on the basis of the fine balance of their surface expression of activating and inhibitory ligands. Among these, the engagement of the NK activatory receptor NKG2D (KLRK1) with a series of stress-induced ligands [e.g., MHC class I–related chain A (MICA), MICB, UL16-binding proteins (ULBP)] expressed on cancer cells appears to have a major role in NK-mediated killing. Target cell destruction is achieved through the activation of death receptors (e.g., FAS and TNFRI-F10) on cancer cells engaged by NK-cell ligands (e.g., FASL and TNFSF10) and/or by the release of cytotoxic granules by NK cells (1). Adaptive immune responses, on the other hand, are antigen specific, involve mainly CD8⁺ and CD4⁺ T lymphocytes, and result in an immunologic memory that allows a more rapid and efficient response at subsequent encounters with the antigen. Within this effector branch of the immune system, CD8⁺ cytotoxic T lymphocytes (CTL) play the main role and, at variance with NK cells, require the engagement of their antigen-specific T-cell receptors (TCR) with TAA presented on neoplastic cell in the form of MHC class I molecule–bound peptides. The generation of the cell surface–bound peptide–MHC complexes is carried out by the antigen processing and presentation machinery (APM) through a multistep process involving (i) generation of peptides through the proteolytic cleavage of TAA by the proteasome [including LMP2 (PSMB9) and LMP7 (PSMB8) subunits]; (ii) translocation of the peptides in the endoplasmic reticulum by the heterodimeric TAP1/TAP2 complex; (iii) loading of MHC class I molecules with peptides, assisted by the chaperones calreticulin (CALR), ERP57 (PDIA3), and tapasin (TAPBP); and (iv) final delivery of MHC class I–peptide complex to the cell surface via the trans-Golgi apparatus. Effective recognition of MHC–peptide complexes by effector T cells further requires tumor cells to express costimulatory/accessory molecules such as CD80, CD86, and ICAM1 that engage their specific counter-receptors on T cells (Fig. 1) (2).

Epigenetically mediated tumor immune escape and tumor immunomodulation by epigenetic drugs

Tumor outgrowth and peripheral immune tolerance to cancer invariably requires transformed cells to acquire immune evasive phenotypes and the capacity to generate an immunosuppressive microenvironment (3, 4). Among the various molecular tools that
tumor cells use to achieve immune escape, triggering of altered epigenetic statuses is a key factor. Indeed, epigenetic modulation through DNA methylation and/or histone posttranslational modifications allows cancer cells to establish heritable, and sometimes extensive, changes in gene expression profiles without altering the gDNA sequence. Epigenetic marks require the activity of specific cellular enzymes to be generated and maintained (Fig. 1): DNA methyl transferases (DNMT) for DNA methylation, and the
Epigenetic gene regulation is finally delivered by the cooperation of promoter DNA methylation, histone deacetylation, and by specific patterns of histone methylation that trigger chromatin condensation leading to gene silencing (Fig. 1; refs. 5–10).

Although limited data are available on their role in establishing an immunosuppressive microenvironment, epigenetic alterations are well-acknowledged to be used by tumor cells to impair their immunogenicity and immune recognition. The latter occurs through the downregulation, either direct or indirect, of the expression of key molecules required for the efficient interaction of cancer cells with the host’s immune system. Epigenetic silencing affects essentially all steps of antigen processing and presentation, including suppression of TAA expression, generation of intratumor TAA heterogeneity, downregulation of TAP1/2 and chaperone molecules, reduced MHC expression, as well as reduced levels of accessory/costimulatory molecules and of surface exposed stress-induced ligands (Fig. 1; reviewed in ref. 11).

The significant role of epigenetics in cancer immune escape provides a strong rationale for the use of epigenetic modifiers to improve immunologic targeting of neoplastic cells and to eventually design more effective cancer immunotherapies (11). Along this line, different epigenetic drugs that can revert epigenetic modifications are available, being currently used in the daily practice or in clinical trials (12–15). Among these, the best characterized are DNMT inhibitors (DNMTi) and HDAC inhibitors (HDACi). DNMTi lead to passive demethylation of gDNA following DNA replication and, among others, comprise 5-azacytidine (Vidaza; Baxter Oncology GmbH/Celgene), 5-aza-2’-deoxycytidine [5-aza-CdR, decitabine, Dacogen (Otsuka America)], zebularine, and RG108. However, second-generation DNMTi [e.g., guadecitabine (SGI-110)] have been recently developed to improve their in vivo stability and to reduce toxicity to normal tissues. On the other hand, HDACi lead to the accumulation of hyperacetylated histones into the chromatin, by shifting the balance of HAT/HDAC activity toward HAT (16). HDACi include sodium butyrate, valproic acid, trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA, vorinostat), LBI589 (panobinostat), FK288 (depsipeptide/romidepsin), and MS-275 (entinostat). Both DNMTi and HDACi have proved effective in inducing/upregulating gene expression in vitro and in vivo, apparently displaying a preferential activity on transformed versus normal cells (17). Furthermore, concomitant use of DNMTi and HDACi can show synergism in gene reexpression/upregulation as expected from the physiologic cooperation of DNA methylation and histone posttranslational modifications in regulating gene expression (18).

Epigenetic drugs have been consistently demonstrated to be able to modulate the immune phenotype of neoplastic cells by affecting one or more key requirements for their efficient immune recognition, independently from tumor histotype. Although DNMTi are undoubtedly the best characterized immunomodulatory epigenetic agents, consistent data are emerging also for HDACi, and to a lesser extend for modulators of histone methylation (recently reviewed in ref. 11). Using mouse and human neoplastic cells, epigenetic drugs have been shown to upregulate essentially all the components of the APM, including (i) TAA [e.g., PMEL, cancer testis antigens (CTA)], for presence, levels, and intratumoral distribution; (ii) the proteasome subunits LMP2 and LMP7; (iii) the TAP1 and TAP2 transporters; (iv) the chaperones ERP57 and calreticulin; and (v) MHC class I and class II molecules. Besides APM, epigenetic agents improved the costimulatory properties of cancer cells by upregulating surface expression of CD40, CD80, CD86, and ICAM1 and restored their sensitivity to immune cell triggered apoptosis by enhancing the expression of death-inducing receptors (e.g., FAS; Fig. 1; refs. 19–22). Although the immunomodulatory activities of DNMTi and of HDACi are frequently overlapping, some preferential tropism of the 2 drug classes can be observed, essentially depending on the prevalent molecular mechanism regulating the specific target molecules. Along this line, induction/upregulation of CTA and ICAM1 is mostly affected by DNMTi, whereas HDACi mainly affect the expression of costimulatory molecules. Of relevance, long-lasting phenotypic immunomodulation appears to be essentially restricted to treatments with DNMTi through their ability to generate heritable changes in gene expression (23). The clinical appeal of these findings relays on the ability of the phenotypic modulations induced by epigenetic compounds to translate into an upregulated functional recognition and killing of tumor cells by antigen-specific CTL, both in vitro and in vivo (11, 20). In addition, HDACi were found particularly effective in inducing a stress response on tumor cells, which led to the upregulated expression on their surface of the NKG2D ligands (MICA, MICB, and ULBPs) and to an increased killing of tumor cells by NK cells (Fig. 1; ref. 24). These observations are undoubtedly not exhaustive of the full immunomodulatory potential of epigenetic drugs as demonstrated by high-throughput gene expression analyses substantiating their broader tumor immunomodulatory activity both in vitro and in vivo (17, 25).

In line with these preclinical data, initial clinical evidence, mainly derived from hematologic malignancies, confirmed the ability of DNMTi to modulate the immune phenotype of cancer cells, inducing long-lasting expression of TAA (26, 27), that can elicit antigen-specific humoral and T-cell immune responses (26, 28).

**Immunogenic cell death**

Another means by which epigenetic drugs can improve immune rejection of cancer stems from their ability to induce immunogenic cell death (ICD). ICD is a newly described form of cell death caused by selected chemotherapeutic drugs. In this context, drug-induced cell death leads to the release of a series of danger-associated molecular signals that label tumor cells as a pathogen, thus rendering them immunogenic. These molecular events finally lead to an increased uptake and immunogenic presentation of tumor antigens by professional antigen-processing cells, which is mandatory for the induction of antitumor T-cell immune responses (29).

Among epigenetic drugs, the ability to induce ICD is mostly a feature of HDACi. Indeed, the pan HDACi vorinostat was proven effective in improving the phagocytosis of colon carcinoma cells by dendritic cells (DC) in vitro and in inducing the release of different ICD mediators, including ATP and HMGB1, and an early surface exposure of the “eat me signal” calreticulin by neoplastic cells of different histology (30, 31). In line with these notions, the anticancer activity of vorinostat and panobinostat was significantly reduced in immunocompromised versus immunocompetent mice, highlighting the requirement of an intact immune system for the full therapeutic activity of the drugs (31). Similarly, when mice were vaccinated with pancreatic carcinoma cells either
Clinical–Translational Advances

The well-established immunomodulatory potential of epigenetic drugs provides a strong scientific rationale to translate it into the clinic by designing novel combination regimens with emerging immunotherapies. This process can be swiftly implemented taking advantage from the recent availability of highly effective immunotherapeutic agents that are being extensively investigated in most solid tumors (33) and by the consolidated clinical use of the DNMTi 5-azacytidine and 5-aza-CdR and the HDACi vorinostat and romidepsin in patients with myelodysplastic syndrome and cutaneous T-cell lymphoma, respectively (12, 34).

Combined epigenetic immunotherapies in the mouse

Preclinical in vivo evidence in different tumor types has begun to show an improved antitumor activity by the concomitant immunomodulation of the tumor and of the host’s immune system by epigenetic and immunotherapeutic drugs, respectively.

Initial approaches investigated combinations with cytokine-based immunotherapy, vaccination with tumor cells either producing cytokines or administered with adjuvants, as well as with peptide vaccines. In these models, the antitumor activity of the different combinations accounted for reductions from 50% to 90% in tumor volumes as compared with untreated mice. The efficacy of treatment was found to be immune mediated as it required CD4+ and CD8+ T and/or NK cells (11, 35–38). Interestingly, in the murine renal cell carcinoma RENCA model, HDACi combined with IL2 was demonstrated to impair the function of the T-regulatory (Treg) immunosuppressive cells, thus synergizing with tumor-infiltrating CD4+ T cells to deplete Treg, to create a highly proinflammatory environment, to deplete Treg, to create a highly proinflammatory environment, and to enhance Pmel-specific T-cell survival (39). Overall, boosting of adoptive cell therapy could take advantage of the concomitant activity of epigenetic drugs on tumor cells, effector cells, and recipient (37, 40, 41). Supporting this hypothesis, the epigenetic induction of the murine CTLA-4 gene was attempted and its proper expression by tumor cells, accounted for a dramatic reduction in the average number of lung metastases observed in the 4T1 syngeneic mammary carcinoma model when an adoptive transfer of anti-TRAP1a CTL was combined with systemic administration of 5-aza-CdR: 72, 72, 32, and 3 lung metastases for mice untreated or treated with anti-TRAP1a CTL, 5-aza-CdR, or their combination were found, respectively (41). On the other hand, the HDACi LAQ824 upregulated MHC class I antigens and Pmel TAA on B16 mouse melanoma grafts, simultaneously improving the activity of adoptively transferred anti-Pmel CTL also through a selective reduction of endogenous competing lymphocytes in the recipient mice. These activities collectively contributed to the synergistic antitumor activity of the HDACi once combined with immunotherapy consisting of anti-Pmel T-cell transfer plus Pmel peptide–pulsed DC vaccine, leading to a significant 70% reduction in tumor volume versus untreated mice, as compared with reductions in tumor volumes of 49% and 21% achieved with immunotherapy or HDACi alone, respectively (40).

The improved understanding of the fine mechanism(s) regulating the physiologic cross-talk among immune cells has recently led to the development of a new therapeutic approach in the clinic: rather than directly targeting tumor cells, monoclonal antibodies (mAb) have been developed to target well-defined inhibitory or activating immune checkpoint molecules expressed on immune cells, thus boosting effective antitumor immune responses (33). This paradigm shift in immunotherapy allowed us to circumvent, at least in part, the immunosuppressive features of neoplastic cells, leading to notable clinical responses also in human malignancies characterized by therapeutic resistance (42). Owing to these results, mAbs blocking the immune checkpoint inhibitors cytotoxic T-lymphocyte antigen 4 (CTLA-4; i.e., ipilimumab) and programmed cell death protein 1 (PD-1, PDCD1; i.e., pembrolizumab and nivolumab) were recently approved for the treatment of advanced cutaneous melanoma (33), as most recently has been nivolumab for chemotherapy-resistant lung cancer. Besides representing the most promising cancer immunotherapeutic tools presently available, mAb targeting immune checkpoints appear to be in synergy or nonallelic with epigenetic combinations with epigenetic drugs. Indeed, an improved antitumor activity could be expected by concomitantly acting on the host’s immune system using an immunomodulatory mAb and at the tumor site using DNMTi and/or HDACi as immunomodulators. Providing experimental support to this hypothesis, combined treatment with the CTLA-4–blocking mAb 9H10 and either 5-aza-CdR (43) or the second-generation DNMTi guadecitabine (44) significantly reduced the growth of poorly immunogenic syngeneic grafts of murine mammary carcinoma TS/A and of mesothelioma AB1 with respect to treatment with the single agents. Compared with control mice, mice treated with 5-aza-CdR, mAb 9H10, or their combination showed tumor growth that was reduced by 54% (P < 0.01), 33% (P = 0.2), and 77% (P < 0.01) in the TS/A model and by 33% (P = 0.10), 0% and 81% (P < 0.05) in the AB1 model, respectively (43). Results consistent with those obtained with 5-aza-CdR were subsequently obtained with SGI-110 in the TS/A model (44). The role of immune mechanism(s) in delivering the improved antitumor effectiveness of the therapeutic combination was supported both by its absence in immunocompromised mice and by the highest degree of infiltrating CD3+ T cells in the tumors of immunocompetent mice undergoing combination therapy (43, 44). The fine molecular and cellular mechanism(s) underlying the improved anticancer activity of the combined treatment remain to be further explored but can be explained, at least in part, by the upregulated expression of TAA and MHC class I antigens induced in tumor grafts by DNMTi (43, 44). In line with these data, combined treatment with 5-azacytidine and entinostat and with checkpoint inhibitors [anti–PD-1 (PCD1) and anti–CTLA-4 (mAb)] markedly improved therapeutic outcomes in syngeneic mammary (i.e., 4T1) and colorectal (i.e., CT26) carcinoma mouse models. Combination therapy eradicated primary tumors in 91% of CT26- and
in 100% of 4T1-bearing mice after 3 weeks and 2 weeks, respectively. Moreover, 4T1-bearing mice that received combination therapy did not develop metastases as compared with mice treated with single agents. In this setting, the improved antitumor activity of the combination was found to be mainly dependent on the elimination of myeloid-derived suppressor cells by the epigenetic drug (45).

The broader potential of mAb targeting immune checkpoints as useful therapeutic partners for epigenetic drugs is further supported by the demonstration that treatment with agonistic mAb against the activating immune checkpoint targets CD40 and CD137 (Trifliti) in combination with vorinostat and panobinostat promoted DC activation, CTL proliferation and survival, being capable of eradicating tumors by CD8+ CTL and NK cells (46). Indeed, anti-CD40 plus anti-CD137 immunotherapy combined with vorinostat delayed the outgrowth of mammary (i.e., 4T1.2), colorectal (i.e., MC38), and renal (i.e., Renca) carcinomas, leading to the eradication of tumors in 25%, 56%, and 25% of mice, respectively. Similar antitumor responses were observed when panobinostat was used instead of vorinostat for the treatment of mice bearing mammary (i.e., 4T1.2), prostate (i.e., MR1), and colon (i.e., CT26) carcinomas.

Although generated in mouse models, these data provide support to the use of novel therapeutic combination(s) with epigenetic drugs to improve the antitumor activity of mAbs against different immune checkpoints, particularly in the context of poorly immunogenic tumors that still represent a major therapeutic challenge.

Clinical perspectives

On the basis of the in vitro and in vivo preclinical data substantiating the immunomodulatory potential of epigenetic drugs and their ability to improve antitumor activity when combined with immunotherapeutic agent(s), several clinical studies are under way to investigate the safety and effectiveness of these novel combinations in patients with cancer (Table 1). Although limited, the clinical results so far available offer valuable insights that could help with the design of epigenetic/immunotherapy combinations. Combining 5-aza-CdR and PF-04648160 in patients with advanced melanoma demonstrated the efficacy of 5-aza-CdR in inducing dGNA hypomethylation at all doses investigated; however, the slow accrual, limited therapeutic efficacy, and significant myelosuppression associated with treatment led to the discontinuation of the trial (47). On the other hand, 5-aza-CdR combined with NY-ESO-1 (CTAG1B) whole protein vaccination and doxorubicin chemotherapy in patients with relapsed ovarian cancer showed limited and manageable toxicities, still providing both global and gene-specific demethylation. Increased humoral and T-cell immune responses were observed against NY-ESO-1 and additional TAA and disease stabilization or partial clinical response occurred in 6 of 10 evaluable patients (48). Overall, both studies confirmed the epigenetic editing ability of DNMTi in patients with cancer and also clearly suggest that careful attention must be paid in designing new studies due to the significant myelotoxocity of DNMTi. The latter undoubtedly represents a major side effect of this class of agents to be taken into consideration and highlights that doses, schedules, and timing of their administration must be carefully reasoned in future studies; nevertheless, ongoing studies will hopefully provide some practical insights on this specific aspect (Table 1). Along this line, a preferred strategy will be represented by the use of DNMTi in combination with immunotherapies, including therapeutic cancer vaccines and mAbs directed to diverse immune checkpoints, due to their substantial nonoverlapping toxicity with epigenetic drugs.

Sparing patients from the toxicity of epigenetic compounds administered systemically, although still taking advantage of their immunomodulatory activity, represents another intriguing strategy. Along this line, the phase I trial NCT01258868 in patients with resectable thoracic cancers foresees the ex vivo treatment of autologous neoplastic cells with 5-aza-CdR to improve their immunogenicity by upregulating a series of molecules, including CTA. In vitro demethylated tumor cells are then emulsified in ISCOMATRIX adjuvant and used to vaccinate patients together with systemic administration of the anti-inflammatory drug celecoxib to improve immune responses by targeting immunosuppressor cells. Although this strategy overcomes the systemic toxicity of epigenetic drugs, a significant limitation derives from the need of autologous tumor tissue to be cultured in vitro to generate the autologous vaccine and from the finite source of vaccinating neoplastic cells; an additional limit to this approach may derive from the lack of in vivo tumor immunomodulation induced by the systemic administration of 5-aza-CdR. These specific issues are not present in other vaccine-based combinations being tested in phase I and phase I/II studies (NCT02332889, NCT01241162, NCT01483274) in different solid tumors and in acute myelogenous leukemias (AML). In these studies, patients are pretreated with 5-aza-CdR to upregulate the expression, processing, and presentation of CTA by the neoplastic cells, aiming to improve their CTA-specific immune recognition boosted by the subsequent vaccination with autologous DC pulsed with CTA peptides (i.e., MAGEA1, MAGEA3, and NY-ESO-1). Although undoubtedly intriguing, a potential drawback of this approach could derive from the limited number of CTA used to pulse DC and against which patients should mount/boost an immune response, thus not taking full advantage of the multiple target CTA that are induced/upregulated on tumor cells in vivo by the systemic administration of 5-aza-CdR. This aspect is being addressed in part by a pilot study in metastatic colorectal cancer in which systemic treatment with guadecitabine is combined with an allogeneic colon cancer cell vaccine (GVAX) that provides multiple potential antigenic targets (NCT01966289). Although the safety of the combination is the primary objective, this study will also evaluate the recruitment of CD45RO+ T cells at the tumor site as a surrogate marker of potential antitumor activity of treatment. Of note, this phase I trial will likely provide initial hints also on the preferable scheduling of treatments by comparing their concurrent administration versus the administration of guadecitabine followed by patient vaccination, which, however, seems to represent a more desirable approach. More comprehensively, the approach of combining CTA-based vaccinations and the administration of epigenetic drugs will likely take further advantage of the availability of the multivalent, CTA-based, immune cell-derived demethylated autologous vaccine DeMethaVax that some of us will bring shortly in the clinic.

The above studies have a clear-cut rationale and promise to improve the effectiveness of therapeutic vaccines a great deal, rejuvenating interest in cancer vaccination. Nevertheless, epigenetic drug combinations with mAb targeting immune checkpoints represents an additional, highly promising, feasible, and intriguing strategy. This notion stems from the convincing preclinical data generated in mouse models, by the significant clinical effectiveness of immunomodulating mAbs as monotherapies,
<table>
<thead>
<tr>
<th>Clinical trial identifier</th>
<th>Title</th>
<th>Recruitment status</th>
<th>Epigenetic drug</th>
<th>Immunotherapy</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUDRACT 2015-001329-17</td>
<td>A phase Ib, open-label, dose-escalation study investigating different doses of guadecitabine in combination with ipilimumab in unresectable or metastatic melanoma patients</td>
<td>Not yet recruiting</td>
<td>Guadecitabine (s.c.)</td>
<td>Ipilimumab</td>
<td>Not submitted</td>
</tr>
<tr>
<td>NCT01834248</td>
<td>DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in treating patients with myelodysplastic syndrome or AML</td>
<td>Recruiting</td>
<td>Decitabine (i.v.)</td>
<td>DEC-205/NY-ESO-1 fusion protein CDX-1401 (s.c. and i.d.) and PolyICLC (s.c.)</td>
<td>First received: April 12, 2013 Last updated: January 15, 2015 Last verified: January 2015</td>
</tr>
<tr>
<td>NCT01928576</td>
<td>Phase II anti–PD-1 epigenetic priming study in NSCLC (NA_00084192)</td>
<td>Recruiting</td>
<td>Azacitidine (s.c.)</td>
<td>Nivolumab</td>
<td>First received: August 21, 2013 Last updated: August 23, 2013 Last verified: August 2013</td>
</tr>
<tr>
<td>NCT01038778</td>
<td>Entinostat in combination with aldesleukin in treating patients with metastatic kidney cancer</td>
<td>Recruiting</td>
<td>Entinostat (p.o.)</td>
<td>Aldesleukin (i.v)</td>
<td>First received: December 18, 2009 Last updated: February 18, 2015 Last verified: December 2014</td>
</tr>
<tr>
<td>NCT02353899</td>
<td>Phase I/II: decitabine/vaccine therapy in relapsed/refractory pediatric high-grade gliomas/medulloblastomas/CNS PNETs</td>
<td>Not yet recruiting</td>
<td>Decitabine (i.v.)</td>
<td>Vaccine (autologous DC pulsed with pooled, overlapping peptide mixes derived from full-length MAGE-A1, MAGE-A3, and NY-ESO-1) and hiltonol (PolyICLC) (i.m.)</td>
<td>First received: October 20, 2014 Last updated: January 5, 2015 Last verified: January 2015</td>
</tr>
<tr>
<td>NCT01483274</td>
<td>Decitabine and vaccine therapy for patients with relapsed AML following allogeneic stem cell transplantation</td>
<td>Not yet recruiting</td>
<td>Decitabine (i.v.)</td>
<td>Donor lymphocyte infusion and dendritic cells pulsed with peptides derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3</td>
<td>First received: November 3, 2011 Last updated: December 1, 2014 Last verified: December 2014</td>
</tr>
<tr>
<td>NCT01673217</td>
<td>Decitabine, vaccine therapy, and PEGylated liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer</td>
<td>Completed</td>
<td>Decitabine (i.v)</td>
<td>NY-ESO-1 peptide vaccine emulsified in incomplete Freund adjuvant and sargramostim (s.c.)</td>
<td>First received: August 22, 2012 Last updated: January 10, 2014 Last verified: January 2014</td>
</tr>
<tr>
<td>NCT01241162</td>
<td>Decitabine followed by a cancer antigen vaccine for patients with neuroblastoma and sarcoma</td>
<td>Recruiting</td>
<td>Decitabine (i.v.)</td>
<td>Autologous DC vaccine pulsed with overlapping peptide mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3 with hiltonol (PolyICLC) (i.v.)</td>
<td>First received: November 15, 2010 Last updated: December 17, 2014 Last verified: December 2014</td>
</tr>
<tr>
<td>NCT01258868</td>
<td>Tumor cell vaccines with ISCOMATRIX adjuvant and cell-based in patients undergoing resection of lung and esophageal cancers and malignant pleural mesotheliomas</td>
<td>Recruiting</td>
<td>Decitabine (i.v.)</td>
<td>Epigenetically modified autologous tumor cell vaccines with ISCOMATRIX (patient tumor cells exposed to decitabine, exposed to radiation and emulsified in ISCOMATRIX adjuvant) (i.m.)</td>
<td>First received: December 10, 2010 Last updated: February 20, 2015 Last verified: February 2015</td>
</tr>
<tr>
<td>NCT01856289</td>
<td>Guadecitabine in combination with an allogeneic colon cancer cell vaccine (GVAX) and cyclophosphamide (i.v.) in metastatic colorectal cancer (mCRC)</td>
<td>Not yet recruiting</td>
<td>Guadecitabine (s.c.)</td>
<td>Allogeneic colon cancer cell vaccine (GVAX) (i.d.) and cyclophosphamide (i.v.)</td>
<td>First received: October 10, 2013 Last updated: October 16, 2015 Last verified: October 2015</td>
</tr>
</tbody>
</table>

Abbreviations: CNS, central nervous system; PNET, primitive neuroectodermal tumor.

*Administration route: i.d., intradermal; l.m., intramuscular; i.v., intravenous; p.o., per os; s.c., subcutaneous.
and by the potential higher reproducibility of results achievable by using already 'industrialized' immunotherapeutics. In addition, even though immune checkpoint inhibitors have demonstrated clear clinical activity in subsets of patients with cancer, additional strategies are needed to extend their benefits to the majority of treated patients; thus, combining them with the tumor immunomodulation induced by epigenetic drugs represents an additional highly rational approach. Along this line, the ongoing NIBIT-M4 trial (EUDRACT 2015-001329-17), combining guadecitabine and the anti–CTLA-4 mAb ipilimumab in metastatic melanoma, will test this intriguing concept through a phase Ib dose escalation design aimed to assess the safety of guadecitabine combined with ipilimumab in patients with previously treated or untreated unresectable or metastatic cutaneous melanoma. At the same time, preliminary signs of biologic and clinical activity will be collected. Along this very same track goes the randomized phase II clinical trial NCT01928576, which is seeking the response rate to regimens including an "epigenetic priming" with azacytidine/oral azacitidine, given alone or in association with the HDACi entinostat, followed by anti–PD-1 immunotherapy with nivolumab in patients with non–small cell lung cancer.

Conclusions

A large body of in vitro experimental evidence has demonstrated that epigenetic drugs have broad cancer immunomodulatory properties, and upcoming preclinical in vivo data are providing sound evidence of their potential to improve the antitumor activity of immunotherapies. Although in its infancy, actively testing this brand new "epigenetic immune-sequencing approach" in the clinic will hopefully provide cancer patients with more effective and long-lasting therapeutic strategies in the future.

Disclosure of Potential Conflicts of Interest

M. Maio is a consultant/advisory board member for AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, MedImmune, and Roche. M. Maio, A. Covre, and S. Coral are listed as co-inventors on a patent-pending application (WO2014/128245) for DNA hypomethylating agents for cancer therapy, which is partially based on findings included in this article. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: L. Sigalotti

Development of methodology: P.G. Natali

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.M. Di Giacomo, P.G. Natali

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E. Fratta, A.M. Di Giacomo, P.G. Natali

Writing, review, and/or revision of the manuscript: M. Maio, A. Covre, E. Fratta, A.M. Di Giacomo, P. Taverna, P.G. Natali, S. Coral, L. Sigalotti

Study supervision: A.M. Di Giacomo

Grant Support

M. Maio was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (IG 11746) and the Italian Ministry of Health. P.G. Natali was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (06/30/C/9).

Received March 16, 2015; revised June 11, 2015; accepted June 18, 2015; published online September 15, 2015.

References

Epigenetic Immunomodulation of Cancer


Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

Michele Maio, Alessia Covre, Elisabetta Fratta, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/21/18/4040

Cited articles
This article cites 47 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/18/4040.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/21/18/4040.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.